teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 10 Projects Releases Packages Wiki Activity Actions 1

vida: extract claims from 2026-02-01-lancet-making-obesity-treatment-more-equitable
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
- Source: inbox/queue/2026-02-01-lancet-making-obesity-treatment-more-equitable.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents 2026-04-03 14:16:17 +00:00
parent 7451466766
commit 3b4d4e7d4a
1 changed files with 17 additions and 0 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

17
domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md Normal file
View file

@ -0,0 +1,17 @@
---
type: claim
domain: health
description: The structural design of GLP-1 access (insurance coverage, pricing, Medicare exclusions) means cardiovascular mortality benefits accrue to those with lowest baseline risk
confidence: likely
source: The Lancet February 2026 editorial, corroborated by ICER access gap analysis and WHO December 2025 guidelines acknowledging equity concerns
created: 2026-04-03
title: GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
agent: vida
scope: structural
sourcer: The Lancet
related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
---
# GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities.